Irene Mikhail1, David R Stukus2, Benjamin T Prince1. 1. Division of Allergy and Immunology, Nationwide Children's Hospital and The Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH, 43205, USA. 2. Division of Allergy and Immunology, Nationwide Children's Hospital and The Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH, 43205, USA. David.stukus@nationwidechildrens.org.
Abstract
PURPOSE OF REVIEW: To provide clinicians with an understanding of risk factors associated with fatal anaphylaxis, and to promote individualized management plans with patients based upon key aspects of their clinical history. RECENT FINDINGS: While anaphylaxis can affect a significant percentage of the general population, death from anaphylaxis remains a rare outcome. The presence of asthma and peanut or tree nut allergy is associated with higher risk for severe or fatal anaphylaxis from foods. Specific triggers (medications, venom), underlying comorbid conditions, age, and use of some medications can also impact risk and warrant different counseling and management strategies. Anaphylaxis is a rapidly progressive systemic reaction with multiple different causes and encompasses a wide degree of severity in clinical presentation and risk for future episodes. Individualized management, discussion of risk, and shared decision making should occur with each patient and in consideration of their personal risk factors.
PURPOSE OF REVIEW: To provide clinicians with an understanding of risk factors associated with fatal anaphylaxis, and to promote individualized management plans with patients based upon key aspects of their clinical history. RECENT FINDINGS: While anaphylaxis can affect a significant percentage of the general population, death from anaphylaxis remains a rare outcome. The presence of asthma and peanut or tree nut allergy is associated with higher risk for severe or fatal anaphylaxis from foods. Specific triggers (medications, venom), underlying comorbid conditions, age, and use of some medications can also impact risk and warrant different counseling and management strategies. Anaphylaxis is a rapidly progressive systemic reaction with multiple different causes and encompasses a wide degree of severity in clinical presentation and risk for future episodes. Individualized management, discussion of risk, and shared decision making should occur with each patient and in consideration of their personal risk factors.
Authors: Simon G A Brown; Shelley F Stone; Daniel M Fatovich; Sally A Burrows; Anna Holdgate; Antonio Celenza; Adam Coulson; Leanne Hartnett; Yusuf Nagree; Claire Cotterell; Geoffrey K Isbister Journal: J Allergy Clin Immunol Date: 2013-08-01 Impact factor: 10.793
Authors: Hugh A Sampson; Anne Muñoz-Furlong; Ronna L Campbell; N Franklin Adkinson; S Allan Bock; Amy Branum; Simon G A Brown; Carlos A Camargo; Rita Cydulka; Stephen J Galli; Jane Gidudu; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Robert O'Connor; Antonella Muraro; Amanda Rudman; Cara Schmitt; Debra Scherrer; F Estelle R Simons; Stephen Thomas; Joseph P Wood; Wyatt W Decker Journal: J Allergy Clin Immunol Date: 2006-02 Impact factor: 10.793
Authors: Robert A Wood; Carlos A Camargo; Philip Lieberman; Hugh A Sampson; Lawrence B Schwartz; Myron Zitt; Charlotte Collins; Michael Tringale; Marilyn Wilkinson; John Boyle; F Estelle R Simons Journal: J Allergy Clin Immunol Date: 2013-10-18 Impact factor: 10.793
Authors: F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm Journal: World Allergy Organ J Date: 2014-05-30 Impact factor: 4.084
Authors: Paul J Turner; Elina Jerschow; Thisanayagam Umasunthar; Robert Lin; Dianne E Campbell; Robert J Boyle Journal: J Allergy Clin Immunol Pract Date: 2017 Sep - Oct